TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Impact of High-volume Veno-venous Continuous Hemofiltration in the Early Management of Septic Shock Patients With Acute Renal Failure
Brief Summary: Sepsis and septic shock are still important causes of mortality in intensive care medicine. Renal replacement therapy by standard volume haemofiltration is currently used, but a higher-volume haemofiltration may improve the prognosis. The study is a prospective randomized multicenter trial comparing two treatments in patients suffering from septic shock complicated with acute renal failure admitted to ICU. One group will be treated by early high volume haemofiltration (70 ml/kg/h) and the second group by standard volume haemofiltration (35 ml/kg/h). The main outcome will be one-month mortality.


Options:
A: Arm Label: high volume hemofiltration; Type: EXPERIMENTAL; Interventions: Procedure: high volume hemofiltration | Arm Label: standard care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard care | Intervention Type: PROCEDURE; Name: high volume hemofiltration; Assigned to Arm(s): high volume hemofiltration | Intervention Type: PROCEDURE; Name: standard care; Assigned to Arm(s): standard care
B: Arm Label: High Volume; Type: EXPERIMENTAL; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Arm Label: Medium Volume; Type: ACTIVE_COMPARATOR; Interventions: Device: Venovenous haemofiltration (renal replacement therapy) | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): High Volume | Intervention Type: DEVICE; Name: Venovenous haemofiltration (renal replacement therapy); Assigned to Arm(s): Medium Volume
C: Arm Label: Intensive renal replacement therapy; Type: EXPERIMENTAL; Interventions: Procedure: renal replacement therapy | Arm Label: Less-intensive renal replacement therapy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: renal replacement therapy | Intervention Type: PROCEDURE; Name: renal replacement therapy; Assigned to Arm(s): Intensive renal replacement therapy, Less-intensive renal replacement therapy
D: Arm Label: Higher intensity CRRT regimen; Type: EXPERIMENTAL; Interventions: Procedure: "augmented" CRRT regimen | Arm Label: Lower intensity CRRT regimen; Type: ACTIVE_COMPARATOR; Interventions: Procedure: "augmented" CRRT regimen | Intervention Type: PROCEDURE; Name: "augmented" CRRT regimen; Assigned to Arm(s): Higher intensity CRRT regimen, Lower intensity CRRT regimen

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study
Brief Summary: Preliminary not-controlled clinical studies of the efficacy of monthly intravenous cyclophosphamide administration in secondary progressive multiple sclerosis reported encouraging results, but no randomized controlled trial has been conducted so far. The primary objective of this trial is to evaluate the efficacy of IV cyclophosphamide as compared to IV methylprednisolone administered every 4 weeks during 1 year and every 8 weeks during 1 year, on the delay to confirmed disability deterioration as assessed by the Expanded Disability Status Scale (EDSS) in patients with secondary progressive multiple sclerosis. The secondary objectives are to evaluate safety, tolerability and efficacy at 2 years on the Multiple Sclerosis Functional Composite (MSFC), the percentage of patients with disability deterioration (EDSS) and the number of relapses. An intention-to-treat statistical analysis will be carried out.


Options:
A: Arm Label: Rituximab; Type: EXPERIMENTAL; Interventions: Drug: Rituximab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: normal saline | Arm Label: Baseline; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: OTHER; Name: normal saline; Assigned to Arm(s): Placebo
B: Arm Label: natalizumab; Type: EXPERIMENTAL; Interventions: Drug: natalizumab | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: natalizumab, Drug: Placebo | Intervention Type: DRUG; Name: natalizumab; Assigned to Arm(s): Placebo, natalizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Threshold estimates; Type: EXPERIMENTAL; Interventions: Other: descriptive case-scenarios | Arm Label: Alternative threshold estimates; Type: ACTIVE_COMPARATOR; Interventions: Other: descriptive case-scenarios | Intervention Type: OTHER; Name: descriptive case-scenarios; Assigned to Arm(s): Alternative threshold estimates, Threshold estimates
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-blind, Two-arm, Multicenter, Randomized Trial to Evaluate Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Recent Secondary Progressive Multiple Sclerosis: P.R.OM.E.S.S Study
Brief Summary: Preliminary not-controlled clinical studies of the efficacy of monthly intravenous cyclophosphamide administration in secondary progressive multiple sclerosis reported encouraging results, but no randomized controlled trial has been conducted so far. The primary objective of this trial is to evaluate the efficacy of IV cyclophosphamide as compared to IV methylprednisolone administered every 4 weeks during 1 year and every 8 weeks during 1 year, on the delay to confirmed disability deterioration as assessed by the Expanded Disability Status Scale (EDSS) in patients with secondary progressive multiple sclerosis. The secondary objectives are to evaluate safety, tolerability and efficacy at 2 years on the Multiple Sclerosis Functional Composite (MSFC), the percentage of patients with disability deterioration (EDSS) and the number of relapses. An intention-to-treat statistical analysis will be carried out.


Options:
A: Arm Label: BG00012 240 mg Twice Daily (BID); Type: EXPERIMENTAL; Interventions: Drug: BG00012, Drug: Placebo | Arm Label: BG00012 240 mg 3 Times Daily (TID); Type: EXPERIMENTAL; Interventions: Drug: BG00012 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD); Type: ACTIVE_COMPARATOR; Interventions: Drug: Glatiramer Acetate | Intervention Type: DRUG; Name: BG00012; Assigned to Arm(s): BG00012 240 mg 3 Times Daily (TID), BG00012 240 mg Twice Daily (BID) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): BG00012 240 mg Twice Daily (BID), Placebo | Intervention Type: DRUG; Name: Glatiramer Acetate; Assigned to Arm(s): Glatiramer Acetate (GA) 20 mg Injection Once Daily (QD)
B: Arm Label: Part I Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Part I BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Arm Label: Part II BG00012; Type: EXPERIMENTAL; Interventions: Drug: dimethyl fumarate | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part I Placebo | Intervention Type: DRUG; Name: dimethyl fumarate; Assigned to Arm(s): Part I BG00012, Part II BG00012
C: Intervention Type: DRUG; Name: rituximab; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cyclophosphamide (drug) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Methylprednisolone (drug) | Intervention Type: DRUG; Name: Cyclophosphamide (drug); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methylprednisolone (drug); Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: : An Open-Label, Randomised, Multi-Centre, Phase IIIb/IV, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin and Atorvastatin in Subjects With Type IIa and IIb Hypercholesterolaemia (DISCOVERY)
Brief Summary: This clinical trial is being performed to investigate the effect of 12 weeks treatment with rosuvastatin and atorvastatin in bringing subjects to their established EAS LDL-C target goal.


Options:
A: Intervention Type: DRUG; Name: Rosuvastatin (Crestor); Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Ezetimibe; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Simvastatin; Assigned to Arm(s): N/A
B: Intervention Type: DRUG; Name: Rosuvastatin; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: MK0653A, ezetimibe (+) simvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Comparator: Rosuvastatin; Assigned to Arm(s): N/A
D: Intervention Type: DRUG; Name: rosuvastatin; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants
Brief Summary: The primary objective of this study is to determine if the GSK Biologicals' human rotavirus (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system \[Ruuska, 1990\]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.

The primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is \>0%.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
B: Arm Label: RotaTeq™ Experimental Formulation; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq™ experimental formulation | Arm Label: RotaTeq™ Existing Formulation; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq™ existing formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ experimental formulation; Assigned to Arm(s): RotaTeq™ Experimental Formulation | Intervention Type: BIOLOGICAL; Name: RotaTeq™ existing formulation; Assigned to Arm(s): RotaTeq™ Existing Formulation
C: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
D: Arm Label: Vaccine Arm; Type: EXPERIMENTAL; Interventions: Biological: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV) | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV); Assigned to Arm(s): Vaccine Arm | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants
Brief Summary: The primary objective of this study is to determine if the GSK Biologicals' human rotavirus (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system \[Ruuska, 1990\]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.

The primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is \>0%.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
B: Intervention Type: BIOLOGICAL; Name: HRV vaccine; Assigned to Arm(s): N/A
C: Arm Label: HIV-uninfected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-uninfected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: HIV-infected RotaTeq; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq | Arm Label: HIV-1 infected Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: RotaTeq; Assigned to Arm(s): HIV-infected RotaTeq, HIV-uninfected RotaTeq | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): HIV-1 infected Placebo, HIV-uninfected Placebo
D: Arm Label: Group 1: Concomitant Administration; Type: EXPERIMENTAL; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Arm Label: Group 2: Sequential Administration; Type: ACTIVE_COMPARATOR; Interventions: Biological: RotaTeq®, Biological: NeisVac-C® | Intervention Type: BIOLOGICAL; Name: RotaTeq®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration | Intervention Type: BIOLOGICAL; Name: NeisVac-C®; Assigned to Arm(s): Group 1: Concomitant Administration, Group 2: Sequential Administration

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Multi-Center Study to Assess the Efficacy, Safety and Immunogenicity of 2 or 3 Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine Given Concomitantly With Routine EPI Vaccinations in Healthy Infants
Brief Summary: The primary objective of this study is to determine if the GSK Biologicals' human rotavirus (HRV) vaccine (pooled HRV groups) given concomitantly with routine expanded program on immunisation (EPI) vaccinations can prevent severe rotavirus gastroenteritis (≥11 on the 20-point Vesikari scoring system \[Ruuska, 1990\]) caused by the circulating wild-type RV strains during the period from 2 weeks after the last dose of HRV vaccine or placebo until Visit 5.

The primary objective will be reached if the lower limit of the 95% confidence interval (CI) on vaccine efficacy is \>0%.

The Protocol Posting has been updated in order to comply with the FDA Amendment Act, Sep 2007.


Options:
A: Arm Label: rotavirus vaccine 116E 1 X 10(4); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Arm Label: rotavirus vaccine 116E 1 X 10(5); Type: EXPERIMENTAL; Interventions: Biological: Oral Rotavirus Vaccine 116E Live Attenuated | Intervention Type: BIOLOGICAL; Name: Oral Rotavirus Vaccine 116E Live Attenuated; Assigned to Arm(s): rotavirus vaccine 116E 1 X 10(4), rotavirus vaccine 116E 1 X 10(5)
B: Intervention Type: BIOLOGICAL; Name: Human rotavirus liquid vaccine; Assigned to Arm(s): N/A
C: Arm Label: Rotarix 3-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™ | Arm Label: Rotarix 2-Dose Group; Type: EXPERIMENTAL; Interventions: Biological: Rotarix™, Biological: Placebo | Arm Label: Placebo Group; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Rotarix™; Assigned to Arm(s): Rotarix 2-Dose Group, Rotarix 3-Dose Group | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Group, Rotarix 2-Dose Group
D: Arm Label: Primary 1: Rotavirus vaccine 6 and 10 weeks; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 1: Rotavirus vaccine 6, 10 and 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 1: Rotavirus vaccine 10 and 14 weeks; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 2: Rotavirus vaccine withholding breast feeding; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Primary 2: Rotavirus vaccine with immediate breast feeding; Type: EXPERIMENTAL; Interventions: Biological: Rotavirus vaccine | Arm Label: Baseline seroconversion for rotavirus; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BIOLOGICAL; Name: Rotavirus vaccine; Assigned to Arm(s): Primary 1: Rotavirus vaccine 10 and 14 weeks, Primary 1: Rotavirus vaccine 6 and 10 weeks, Primary 1: Rotavirus vaccine 6, 10 and 14 weeks, Primary 2: Rotavirus vaccine with immediate breast feeding, Primary 2: Rotavirus vaccine withholding breast feeding

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Fluorescence-guided Resection of Malignant Gliomas With 5-Aminolevulinic Acid (5-ALA) vs. Conventional Resection
Brief Summary: The aim of the study "Fluorescence-guided resection of malignant gliomas with 5-Aminolevulinic acid (5-ALA) vs. conventional resection" is to determine how accurately contrast agent-accumulating tumour can be removed by primary surgery and to assess the clinical usefulness of this method.


Options:
A: Arm Label: 5-aminolevulinic acid; Type: EXPERIMENTAL; Interventions: Drug: 5-aminolevulinic acid (5-ALA) | Arm Label: Conventional resection; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: 5-aminolevulinic acid (5-ALA); Assigned to Arm(s): 5-aminolevulinic acid
B: Arm Label: Rindopepimut/GM-CSF plus Temozolomide; Type: EXPERIMENTAL; Interventions: Drug: Rindopepimut (CDX-110) with GM-CSF, Drug: Temozolomide | Arm Label: KLH plus Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide, Drug: KLH | Intervention Type: DRUG; Name: Rindopepimut (CDX-110) with GM-CSF; Assigned to Arm(s): Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): KLH plus Temozolomide, Rindopepimut/GM-CSF plus Temozolomide | Intervention Type: DRUG; Name: KLH; Assigned to Arm(s): KLH plus Temozolomide
C: Arm Label: Temozolomide; Type: ACTIVE_COMPARATOR; Interventions: Drug: temozolomide, Genetic: DNA methylation analysis, Procedure: quality-of-life assessment | Arm Label: Radiation; Type: ACTIVE_COMPARATOR; Interventions: Genetic: DNA methylation analysis, Procedure: quality-of-life assessment, Radiation: Radiation | Intervention Type: DRUG; Name: temozolomide; Assigned to Arm(s): Temozolomide | Intervention Type: GENETIC; Name: DNA methylation analysis; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: PROCEDURE; Name: quality-of-life assessment; Assigned to Arm(s): Radiation, Temozolomide | Intervention Type: RADIATION; Name: Radiation; Assigned to Arm(s): Radiation
D: Arm Label: NovoTTF-100A device in combination with Temozolomide; Type: EXPERIMENTAL; Interventions: Device: NovoTTF-100A device | Arm Label: Temozolomide alone, as the best known standard of care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Temozolomide | Intervention Type: DEVICE; Name: NovoTTF-100A device; Assigned to Arm(s): NovoTTF-100A device in combination with Temozolomide | Intervention Type: DRUG; Name: Temozolomide; Assigned to Arm(s): Temozolomide alone, as the best known standard of care

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Preschool Based Obesity Prevention Effectiveness Trial
Brief Summary: The purpose of this study is to compare changes in body mass index (BMI) among 3- to 5-year-old minority children randomized to a weight control intervention (WCI) or a general health control intervention.


Options:
A: Arm Label: Physical activity intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Physical activity intervention | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Usual practice | Intervention Type: BEHAVIORAL; Name: Physical activity intervention; Assigned to Arm(s): Physical activity intervention | Intervention Type: BEHAVIORAL; Name: Usual practice; Assigned to Arm(s): Control
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: 6 months of healthy physical activity | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: 6 months of healthy physical activity; Assigned to Arm(s): 1
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Behavioral: Primary (Environmental) Weight Gain Prevention, Behavioral: Secondary (Behavioral) Weight Gain Prevention | Arm Label: Arm 3; Type: EXPERIMENTAL; Interventions: Behavioral: Control | Intervention Type: BEHAVIORAL; Name: Primary (Environmental) Weight Gain Prevention; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: BEHAVIORAL; Name: Secondary (Behavioral) Weight Gain Prevention; Assigned to Arm(s): Arm 2 | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Arm 3
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Teacher-Delivered Weight Control Intervention | Arm Label: 2; Type: OTHER; Interventions: Behavioral: Teacher-Delivered General Health Intervention | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered Weight Control Intervention; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Teacher-Delivered General Health Intervention; Assigned to Arm(s): 2

Answer: D